Skip to main content

In Brief This Week: Biosynth, Baby Genes, Immunovia, and More

NEW YORK (360Dx) – Biosynth and Ramot, the Tel Aviv University Business Engagement Center, announced this week that they have incorporated a joint venture called Nemis Technologies to jointly develop diagnostic kits and solutions for rapid pathogenic bacteria detection for food safety, water treatment, hospital, and clinical applications. The base technology, called AquaSpark, enables highly sensitive chemiluminescence probes for research and diagnostic applications, the partners said.


Baby Genes said this week that it has received CAP accreditation. The firm provides NGS-based clinical diagnostics for newborn screening, newborn diagnostic testing, and family planning. During the accreditation process, a company's clinical lab records and quality control procedures are assessed by inspectors, as well as its equipment, facilities, safety programs, staff qualifications, policies and procedures, and overall management.


Immunovia announced that Linköping University Hospital is now participating in PanFAM-1, a prospective study looking at early diagnosis in high-risk individuals with familial pancreatic cancer. The study is designed to validate Immunovia's IMMray PanCan-d blood test, and will analyze more than 1,000 individuals over three years across sites in Sweden, the US, and Europe already offering FPC screening programs, with the aim of proving the overall healthcare benefits of testing hereditary pancreatic cancer patients. The other PanFAM-1 partners to date are Mount Sinai, the Knight Cancer Institute at Oregon Health and Sciences University, the University of Pittsburgh Medical Center, Massachusetts General Hospital, NYU School of Medicine, the University of Liverpool, Ramon y Cajal Institute for Health Research, University Hospital of Santiago de Compostela, Clinica Universidad de Navarra, and Sahlgrenska University.


Centogene said that it has inked a deal to collaborate with Orphazyme to support Orphazyme’s clinical trials in India on a small molecule, arimoclomol, for the treatment of neuronopathic Gaucher disease. Centogene will process and analyze different sample types from patients participating in the trial, including plasma, cerebrospinal fluid, and dried blood spots from Centogene's CentoCard. The partners are also utilizing lysoGb1, a biomarker for Gaucher disease that Centogene developed and validated, as a monitoring tool during the trial.


Thermo Fisher Scientific said this week that its board has declared a quarterly cash dividend of $.17 per common share, payable on July 16 to shareholders of record as of June 15.


Luminex said that its board has declared a cash dividend of $.06 per share, payable on July 13 to stockholders of record as of June 22.


In a filing with the US Securities and Exchange Commission this week, Biocept reported that it is planning a $25 million subscription rights offering to holders of its common stock and warrants that were issued on Feb. 13, 2015; May 4, 2016; Oct. 19, 2016; March 31, 2017; Aug. 9, 2017; and Jan. 30, 2018. The holders of these shares and warrants would receive subscription rights to purchase units, each of which would consist of one share of Series A convertible preferred stock and an as-yet unspecified number of warrants, according to Biocept's SEC filing. Each warrant would then be exercisable for one share of the firm's common stock. Maxim Group and Dawson James Securities are acting as co-dealer managers in the rights offering.


 

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.